GlobeNewswire: ProPhase Labs, Inc. Contains the last 10 of 185 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:06:29ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/15/2847009/0/en/ProPhase-Labs-Announces-Financial-Results-for-the-Year-Ended-December-31-2023-and-Significant-Progress-in-Its-Strategic-Initiatives.html?f=22&fvtc=4&fvtv=37103ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives2024-03-15T12:00:00Z<![CDATA[Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages]]>https://www.globenewswire.com/news-release/2024/03/08/2843085/0/en/PROPHASE-LABS-TO-PRESENT-2023-YEAR-END-FINANCIAL-RESULTS-ON-MARCH-15-2024.html?f=22&fvtc=4&fvtv=37103PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 20242024-03-08T13:00:00Z<![CDATA[GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted by Renmark Financial on March 15, 2024 at 11:00 am EDT. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.]]>https://www.globenewswire.com/news-release/2024/02/20/2831780/0/en/ProPhase-Labs-Announces-Significant-Progress-in-BE-Smart-Esophageal-Cancer-Test-Development-USPTO-grants-additional-broad-patents-for-BE-SMART.html?f=22&fvtc=4&fvtv=37103ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART2024-02-20T13:00:00Z<![CDATA[Garden City, NY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the Company’s efforts to commercialize its novel BE-SMART esophageal cancer diagnostic test.]]>https://www.globenewswire.com/news-release/2024/02/14/2829018/0/en/ProPhase-Labs-Announces-Preliminary-Positive-Results-for-Dietary-Supplement-Equivir.html?f=22&fvtc=4&fvtv=37103ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir2024-02-14T13:00:00Z<![CDATA[Commercialization of Equivir anticipated after second trial is completed in Q2, 2024]]>https://www.globenewswire.com/news-release/2024/01/30/2819949/0/en/ProPhase-Labs-Ushers-in-New-Genomics-Era-with-Jason-Karkus-at-the-Helm-of-Nebula-Genomics.html?f=22&fvtc=4&fvtv=37103ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics2024-01-30T13:00:00Z<![CDATA[Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.]]>https://www.globenewswire.com/news-release/2024/01/23/2814037/0/en/Pharmaloz-Manufacturing-Accelerates-Expansion-Improves-Pricing-Boosts-Profitability-and-Secures-New-Contracts.html?f=22&fvtc=4&fvtv=37103Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts2024-01-23T13:00:00Z<![CDATA[Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and ProfitabilityCompany in Late-Stage Discussions with Two Additional Large Global Brands Which, if Consummated, Could more than Triple Run-Rate of Revenues Before Year-End 2024]]>https://www.globenewswire.com/news-release/2024/01/04/2803949/0/en/ProPhase-poised-to-ramp-up-growth-at-Pharmaloz-and-Nebula-Genomics-in-2024.html?f=22&fvtc=4&fvtv=37103ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 20242024-01-04T13:00:00Z<![CDATA[Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed Latkin as COO to help build and manage this growth]]>https://www.globenewswire.com/news-release/2023/11/09/2777297/0/en/ProPhase-Labs-Announces-Financial-Results-for-the-Three-Months-Ended-September-30-2023.html?f=22&fvtc=4&fvtv=37103ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 20232023-11-09T13:00:00Z<![CDATA[Company sees significant momentum in Pharmaloz, Nebula Genomics and ProPhase BioPharma]]>https://www.globenewswire.com/news-release/2023/11/02/2772206/0/en/ProPhase-Labs-to-Host-Third-Quarter-2023-Financial-Results-Conference-Call-on-Thursday-November-9-2023-at-11-00-a-m-Eastern-Time.html?f=22&fvtc=4&fvtv=37103ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time2023-11-02T12:00:00Z<![CDATA[GARDEN CITY, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursday, November 9, 2023, at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2023 and provide a business update. A press release detailing these results will be issued prior to the call.]]>https://www.globenewswire.com/news-release/2023/10/17/2761436/0/en/ProPhase-Labs-Announces-Substantial-Growth-Expectations-for-Pharmaloz-Manufacturing-Subsidiary-due-to-Skyrocketing-Demand-for-Pharmaloz-Output.html?f=22&fvtc=4&fvtv=37103ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.2023-10-17T12:00:00Z<![CDATA[Pharmaloz plan is to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by year-end 2024, with 20-25% pre-tax net margins and a goal for additional growth thereafter.]]>